Michael L. Meyers's most recent trade in Nuvalent Inc - Ordinary Shares - Class A was a trade of 4,147 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nuvalent Inc - Ordinary Sh... | Michael L. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 4,147 | 4,147 | - | - | Stock Option (Right to Buy) | |
| Nuvalent Inc - Ordinary Sh... | Michael L. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 2,647 | 5,146 | - | 0 | Class A Common Stock | |
| Nuvalent Inc - Ordinary Sh... | Michael L. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 3,789 | 3,789 | - | - | Stock Option (Right to Buy) | |
| Nuvalent Inc - Ordinary Sh... | Michael L. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,499 | 2,499 | - | 0 | Class A Common Stock | |
| Nuvalent Inc - Ordinary Sh... | Michael L. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Nuvalent Inc - Ordinary Sh... | Michael L. Meyers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Syndax Pharmaceuticals Inc | Michael L. Meyers | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 17,350 | 17,350 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Michael L. Meyers | SVP, Chief Medical Officer | Other type of transaction at price $ 12.39 per share. | 02 Feb 2022 | 1,714 | 23,280 (0%) | 0% | 12.4 | 21,236 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael L. Meyers | SVP, Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 15.46 per share. | 26 Apr 2021 | 500 | 15,666 (0%) | 0% | 15.5 | 7,730 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael L. Meyers | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Syndax Pharmaceuticals Inc | Michael L. Meyers | SVP, Chief Medical Officer | Other type of transaction at price $ 7.97 per share. | 03 Feb 2021 | 2,665 | 13,395 (0%) | 0% | 8.0 | 21,240 | Common Stock |
| Syndax Pharmaceuticals Inc | Michael L. Meyers | SVP, Chief Medical Officer | Other type of transaction at price $ 12.00 per share. | 03 Feb 2021 | 1,771 | 15,166 (0%) | 0% | 12 | 21,252 | Common Stock |